OPEN APP
Home >Companies >Syngene sets up R&D lab for Amgen in Bengaluru
Shares of Syngene dropped 0.18% to close at `472.35 on BSE, while the benchmark Sensex gained 1.56% to end 28,978.02 points.
Shares of Syngene dropped 0.18% to close at `472.35 on BSE, while the benchmark Sensex gained 1.56% to end 28,978.02 points.

Syngene sets up R&D lab for Amgen in Bengaluru

Syngene Amgen Research and Development Center, will be Syngene's fourth exclusive R&D center

Hyderabad: Syngene International Ltd, the contract research services arm of Biocon Ltd, is setting up a drug discovery and development center in Bengaluru for Amgen Inc., a biotechnology company based in the US.

Named Syngene Amgen Research and Development Center (SARC), will be Syngene’s fourth such exclusive research and development (R&D) center. It already operates dedicated R&D centers for international companies such as Bristol-Myers Squibb, Abbott Nutrition and Baxter Inc.

“The state-of-the-art dedicated center will be staffed by a team of more than 100 highly qualified Syngene scientists, working in close association with Amgen researchers around the world on the discovery and development of innovative medicines," Syngene said in a statement.

“In addition to being customized to meet Amgen’s functional requirements, the facility complies with the highest regulatory standards. Its design includes a range of environmentally-friendly features and flexible layouts, and is configured to minimize solvent and effluent waste with a strong emphasis on laboratory safety and green chemistry," the statement added.

Syngene has partnered with Amgen in a variety of discovery and development projects. With the establishment of SARC, this association now extends into a multi-discipline collaboration spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharmaceutical development.

California-based Amgen is one of the world’s largest biotech companies. It had revenue of around $21.7 billion in 2015 and spends about 18% of it on R&D.

Syngene has managed to boost its client base to 256 from 221 a year earlier. Its top three clients—Bristol, Abbott and Baxter—account for around 40% of its revenue.

Syngene has committed to spend around $200 million on capital expenditure over the next three years as part of a broader plan to evolve from a contract research firm into a contract research and manufacturing services company with commercial-scale production capabilities.

Shares of Syngene dropped 0.18% to close at 472.35 on BSE, while the benchmark Sensex gained 1.56% to end 28,978.02 points.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
Edit Profile
My ReadsRedeem a Gift CardLogout